Protocol Ledger

NCT04773067 · Phase II · TERMINATED

A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers

Interventional Phase II clinical trial protocol NCT04773067 sponsored by United Biomedical Inc., Asia in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-30 Enrollment: 3,877 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04773067
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,877 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04773067
Protocol FieldVerified Registry Value
NCT IdentifierNCT04773067
Consolidated Lead SponsorUnited Biomedical Inc., Asia
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment3,877 participants (ACTUAL)
Registered Start Date2021-01-30
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04773067
Hospital Research SiteLocationSite Profile
Changhua Christian HospitalChanghua, TaiwanOpen Hospital Dossier ->
Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
Kaohsiung Veterans General HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
China Medical University HospitalTaichung, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI